Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
IDNT TRIAL |
|
|---|---|
| Problem | Diabetic nephropathy (T2DM) |
| Format | - |
| Treatment | Irbesartan |
| Control | Placebo |
| Population | 590 |
| Inclusion criteria | - |
| Exclusion criteria | - |
| Follow-up | 2 years |
| Primary endpoint | Composite of doubling serum creatinine, end stage renal failure and mortality |
| Secondary endpoint(s) | - |
| Details | - |
| Brief summary: | |
| PAPER: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. | |
|---|---|
| Date | 20 Sep 2001 |
| Journal | N Engl J Med. 2001 Sep 20;345(12):870-8. |
| Information | Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria. |
| PAPER: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. | |
|---|---|
| Date | 1 Apr 2003 |
| Journal | Ann Intern Med. 2003 Apr 1;138(7):542-9. |
| Information | Composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy. |